Related Experiment Video

Updated: Sep 3, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

The Role of CDK Pathway Dysregulation and Its Therapeutic Potential in Soft Tissue Sarcoma

Johannes Tobias Thiel1, Adrien Daigeler1, Jonas Kolbenschlag1

  • 1Department of Hand, Plastic, Reconstructive and Burn Surgery, BG Unfallklinik Tuebingen, University of Tuebingen, 72076 Tuebingen, Germany.

Cancers
|July 27, 2022
PubMed

Insights

Soft tissue sarcomas (STSs) are complex tumors. Targeting cyclin-dependent kinases (CDKs) shows promise for treating STSs by regulating cell growth and gene expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Soft tissue sarcomas (STSs) exhibit significant heterogeneity, complicating treatment.
  • Cyclin-dependent kinase (CDK) signaling pathways are increasingly recognized as key drivers of sarcoma development.
  • CDKs regulate cell-cycle control and gene expression, making them critical in cancer progression.

Purpose of the Study:

  • To review the role of CDK signaling in STS pathogenesis.
  • To summarize current therapeutic strategies targeting CDK modulation for STS treatment.
  • To explore the potential of reversing CDK dysregulation in STSs.

Main Methods:

  • Literature review of studies on CDK signaling in soft tissue sarcomas.
  • Analysis of research on CDK/cyclin complexes in cell-cycle regulation and gene expression.
  • Examination of evidence for CDK modulation as a therapeutic approach for STSs.

Main Results:

  • Dysregulation of CDK signaling pathways is a common feature across various STS subtypes.
  • CDKs are crucial for the proliferation and growth of sarcoma cells.
  • Modulation of CDK activity presents a promising therapeutic avenue for STS treatment.

Conclusions:

  • Targeting CDK signaling pathways offers a potential strategy for managing STSs.
  • Further research into CDK inhibitors could lead to novel treatments for these challenging tumors.
  • Understanding CDK regulation is key to developing effective therapies for soft tissue sarcomas.
Keywords:
CDKCDK inhibitorsCKIcyclin-dependent kinasesarcomasoft tissue sarcoma

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.6K